

***Core indicators for monitoring the Ending the HIV Epidemic initiative
(preliminary data): HIV diagnoses and linkage to HIV medical care, 2019 and
2020 (preliminary data) reported through June 2020***

Advisory Statement

Effective date: May 21, 2024

Publication date of referenced document: October 2020

Preexposure prophylaxis (PrEP) coverage is currently estimated by taking the number of persons prescribed PrEP (numerator) and dividing it by the estimated number of persons with indications for PrEP (denominator). Since the current methodology for estimating PrEP coverage was first published in 2018, CDC has cited limitations of both the numerator and denominator. For example, the number of persons prescribed PrEP is estimated by using data from the IQVIA pharmacy database based on an algorithm that includes FDA-approved drugs for PrEP. Although IQVIA records 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States, data from closed health care systems are not included in the IQVIA data set. Therefore, the current PrEP numerator has represented minimum estimates of PrEP prescriptions. Additionally, race/ethnicity data in the IQVIA database are only available for <40% of persons prescribed PrEP each year. Regarding limitations of the current denominator, the number of persons who have indications for PrEP is estimated by using data from 3 sources: National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Each of these data sources have different schedules of data availability. As a result, the availability of a denominator often lags the availability of a numerator.

In March 2024, updated data from 2 closed-system sources were made available to CDC that can improve the representativeness of the number of persons prescribed PrEP in the United States. In the coming months, CDC also expects to have updates to the data sets currently used to estimate the number of persons with indications for PrEP. To ensure that PrEP coverage estimates are calculated using the best available data at the time of publication, CDC is pausing PrEP coverage reporting for one year. During this time, CDC will update PrEP coverage data sources and determine the best way to present PrEP coverage. CDC plans to resume PrEP coverage reporting in the next HIV Surveillance Supplemental (Monitoring) Report, currently scheduled for publication in June 2025.

Until updated estimates are published, CDC advises against citing specific PrEP coverage data points and instead recommends referencing general trends and disparities. In addition, because of a formula error that affects a subset of race and ethnicity PrEP data, race and ethnicity data points from all reports published prior to 2024 should not be cited.



Vol. 1, No. 6

**Core Indicators for Monitoring the
Ending the HIV Epidemic Initiative
(*Preliminary Data*):**

**HIV Diagnoses and Linkage to
HIV Medical Care, 2019 and 2020
(Reported through June 2020)**

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through June 2020.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative: HIV diagnoses and linkage to HIV medical care, 2019 and 2020 (preliminary data reported through June 2020). *HIV Surveillance Data Tables* 2020;1(No. 6). <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published October 2020. Accessed [date].

On the Web: <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>

Confidential information, referrals, and educational material on HIV infection and AIDS

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Xiaohong Hu, Jianmin Li, Baohua Wu, Chan Jin, Shihua Wang, Chenchen Yu, Irene Hall, Norma Harris, and Michael Friend and the Web and Consumer Services Team of the Prevention Communications Branch (editing and desktop publishing).

Technical Notes	4
References	5
Tables	
1a Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2019 through June 2020—United States (preliminary)	6
1b Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2019 through June 2020—United States and 6 dependent areas (preliminary)	7
1c Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2019 through June 2020—United States and 6 dependent areas (preliminary)	8
1d Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2019 through June 2020—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	9
2a Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥ 13 years, by selected characteristics—41 states and the District of Columbia (preliminary)	11
2b Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥ 13 years, by area of residence—41 states and the District of Columbia (preliminary)	13
2c Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	15

The *Ending the HIV Epidemic: A Plan for America* (EHE) initiative will leverage critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% in 5 years and by at least 90% in 10 years. Throughout the initiative, the Centers for Disease Control and Prevention (CDC) will routinely release *HIV Surveillance Data Tables* on the 6 core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report at <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-1-no-1/index.html>.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care reported to CDC as of June 2020 for the years 2019 and 2020. Data for both indicators are provided at the national-, state-, and county-levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. Data reported to the National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting lag has been reached. Because the data in this report are provided by using an NHSS dataset produced prior to reaching a 12-month reporting lag, the data should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions [2].

TABULATION AND PRESENTATION OF DATA

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥ 13 years whose HIV infection was diagnosed during January 2019 through June 2020 (Tables 1a–d).

Data presented were reported (after the removal of personally identifiable information) to CDC’s NHSS through June 2020. Please use caution when interpreting data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection

could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state and local jurisdictions.

More information on counting diagnoses of HIV infection can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-31/index.html> (*HIV Surveillance Report, 2018 [Updated]*).

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years whose HIV infection was diagnosed during January 2019 through March 2020, and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during the specified year, and who had ≥ 1 CD4 or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during the specified year. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data for the year 2020 on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January through March of 2020 and that were reported to NHSS through June 2020. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

More information on calculating linkage to care can be found at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-2.pdf> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018*).

REFERENCES

1. HHS. What is ‘Ending the HIV Epidemic: A Plan for America’? <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Published October 4, 2019. Accessed July 13, 2020.
2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. *MMWR* 2020;69(18):551–556. doi:<http://dx.doi.org/10.15585/mmwr.mm6918e2>

Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2019 through June 2020—United States (preliminary)

	2019 Total No.	2020 (January–June) Total No.
Gender		
Male	28,217	8,292
Female	6,721	1,946
Transgender male-to-female ^a	575	164
Transgender female-to-male ^a	41	8
Additional gender identity ^b	20	4
Age at diagnosis (yr)		
13–24	7,384	2,063
25–34	12,788	3,797
35–44	6,935	1,995
45–54	4,764	1,437
≥ 55	3,703	1,122
Race/ethnicity		
American Indian/Alaska Native	210	58
Asian	731	210
Black/African American	15,375	4,710
Hispanic/Latino ^c	9,384	2,528
Native Hawaiian/other Pacific Islander	68	23
White	9,028	2,752
Multiple races	778	133
Transmission category^d		
Male-to-male sexual contact	23,574	7,017
Injection drug use		
Male	1,349	411
Female	1,079	288
Male-to-male sexual contact and injection drug use	1,314	339
Heterosexual contact ^e		
Male	2,538	683
Female	5,656	1,653
Other ^f		
Male	34	10
Female	31	14
Region of residence^g		
Northeast	5,257	1,243
Midwest	4,745	1,447
South	18,516	5,797
West	7,056	1,927
Total	35,574	10,414

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

^a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2019 through June 2020—United States and 6 dependent areas (preliminary)

	2019 Total No.	2020 (January–June) Total No.
Gender		
Male	28,530	8,353
Female	6,796	1,953
Transgender male-to-female ^a	577	165
Transgender female-to-male ^a	41	8
Additional gender identity ^b	20	4
Age at diagnosis (yr)		
13–24	7,442	2,075
25–34	12,894	3,821
35–44	7,011	2,006
45–54	4,830	1,447
≥55	3,787	1,134
Race/ethnicity		
American Indian/Alaska Native	210	58
Asian	737	210
Black/African American	15,380	4,710
Hispanic/Latino ^c	9,752	2,596
Native Hawaiian/other Pacific Islander	72	23
White	9,034	2,753
Multiple races	779	133
Transmission category^d		
Male-to-male sexual contact	23,789	7,062
Injection drug use		
Male	1,377	419
Female	1,084	288
Male-to-male sexual contact and injection drug use	1,325	341
Heterosexual contact ^e		
Male	2,599	690
Female	5,726	1,659
Other ^f		
Male	34	10
Female	31	14
Region of residence^g		
Northeast	5,257	1,243
Midwest	4,745	1,447
South	18,516	5,797
West	7,056	1,927
U.S. dependent areas	390	69
Total	35,964	10,483

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

^a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 1c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2019 through June 2020—United States and 6 dependent areas (preliminary)

Area of residence	2019	2020
	Total No.	(January–June) Total No.
Alabama	596	221
Alaska	27	15
Arizona	766	290
Arkansas	284	120
California	4,198	1,061
Colorado	459	117
Connecticut	212	40
Delaware	92	48
District of Columbia	249	62
Florida	4,405	1,648
Georgia	2,291	524
Hawaii	63	12
Idaho	27	1
Illinois	1,257	290
Indiana	490	178
Iowa	100	35
Kansas	132	38
Kentucky	268	57
Louisiana	889	331
Maine	29	4
Maryland	917	277
Massachusetts	521	95
Michigan	675	213
Minnesota	273	100
Mississippi	460	172
Missouri	487	168
Montana	25	3
Nebraska	81	26
Nevada	509	85
New Hampshire	31	11
New Jersey	1,029	140
New Mexico	147	31
New York	2,340	659
North Carolina	1,376	499
North Dakota	36	9
Ohio	972	302
Oklahoma	243	62
Oregon	198	69
Pennsylvania	1,010	276
Rhode Island	702	282
South Carolina	74	12
South Dakota	34	8
Tennessee	776	284
Texas	4,002	882
Utah	135	48
Vermont	11	6
Virginia	822	281
Washington	489	191
West Virginia	144	47
Wisconsin	208	80
Wyoming	13	4
Subtotal	35,574	10,414
U.S. dependent areas		
American Samoa	0	0
Guam	10	0
Northern Mariana Islands	2	0
Puerto Rico	372	69
Republic of Palau	0	0
U.S. Virgin Islands	6	0
Subtotal	390	69
Total	35,964	10,483

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2019 through June 2020—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	2019 Total No.	2020 (January–June) Total No.
Arizona		
Maricopa County	525	196
California		
Alameda County	223	73
Los Angeles County	1,409	373
Orange County	246	104
Riverside County	262	61
Sacramento County	84	3
San Bernardino County	273	33
San Diego County	361	66
San Francisco County	207	62
District of Columbia	249	62
Florida		
Broward County	598	218
Duval County	272	98
Hillsborough County	267	136
Miami-Dade County	1,158	378
Orange County	471	183
Palm Beach County	237	102
Pinellas County	187	83
Georgia		
Cobb County	170	27
DeKalb County	327	64
Fulton County	565	145
Gwinnett County	194	32
Illinois		
Cook County	893	213
Indiana		
Marion County	209	70
Louisiana		
East Baton Rouge Parish	152	63
Orleans Parish	159	42
Maryland		
Baltimore City	192	64
Montgomery County	141	37
Prince George's County	271	77
Massachusetts		
Suffolk County	134	31
Michigan		
Wayne County	285	99
Nevada		
Clark County	448	64
New Jersey		
Essex County	224	43
Hudson County	148	18

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2019 through June 2020—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	2019 Total No.	2020 (January–June) Total No.
New York		
Bronx County	500	119
Kings County	474	160
New York County	343	103
Queens County	356	109
North Carolina		
Mecklenburg County	268	82
Ohio		
Cuyahoga County	158	59
Franklin County	217	79
Hamilton County	171	41
Pennsylvania		
Philadelphia County	431	112
Puerto Rico		
San Juan Municipio	85	13
Tennessee		
Shelby County	262	108
Texas		
Bexar County	356	112
Dallas County	738	257
Harris County	1,100	120
Tarrant County	292	78
Travis County	180	58
Washington		
King County	252	106

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 2a. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥13 years, by selected characteristics—41 states and the District of Columbia (preliminary)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2019					
Gender					
Male	25,292	20,727	82.0	4,565	18.0
Female	5,966	4,783	80.2	1,183	19.8
Transgender male-to-female ^a	523	434	83.0	89	17.0
Transgender female-to-male ^a	36	31	86.1	5	13.9
Additional gender identity ^b	18	16	88.9	2	11.1
Age at diagnosis (yr)					
13–24	6,618	5,264	79.5	1,354	20.5
25–34	11,471	9,303	81.1	2,168	18.9
35–44	6,213	5,134	82.6	1,079	17.4
45–54	4,246	3,542	83.4	704	16.6
≥55	3,287	2,748	83.6	539	16.4
Race/ethnicity					
American Indian/Alaska Native	167	140	83.8	27	16.2
Asian	661	548	82.9	113	17.1
Black/African American	14,005	11,060	79.0	2,945	21.0
Hispanic/Latino ^c	8,380	7,080	84.5	1,300	15.5
Native Hawaiian/other Pacific Islander	64	52	81.3	12	18.8
White	7,849	6,518	83.0	1,331	17.0
Multiple races	709	593	83.6	116	16.4
Transmission category^d					
Male-to-male sexual contact	21,288	17,558	82.5	3,729	17.5
Injection drug use					
Male	1,108	854	77.1	253	22.9
Female	927	702	75.7	225	24.3
Male-to-male sexual contact and injection drug use	1,152	926	80.4	225	19.6
Heterosexual contact ^e					
Male	2,251	1,808	80.3	443	19.7
Female	5,052	4,091	81.0	961	19.0
Total^f	31,835	25,991	81.6	5,844	18.4

Table 2a. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥13 years, by selected characteristics—41 states and the District of Columbia (preliminary) (cont)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2020 (January–March)					
Gender					
Male	5,370	4,349	81.0	1,021	19.0
Female	1,224	998	81.5	226	18.5
Transgender male-to-female ^a	106	88	83.0	18	17.0
Transgender female-to-male ^a	4	4	100	0	0.0
Additional gender identity ^b	3	3	100	0	0.0
Age at diagnosis (yr)					
13–24	1,318	1,024	77.7	294	22.3
25–34	2,441	1,987	81.4	454	18.6
35–44	1,326	1,076	81.1	250	18.9
45–54	922	760	82.4	162	17.6
≥55	700	595	85.0	105	15.0
Race/ethnicity					
American Indian/Alaska Native	34	29	85.3	5	14.7
Asian	140	121	86.4	19	13.6
Black/African American	3,080	2,432	79.0	648	21.0
Hispanic/Latino ^c	1,636	1,352	82.6	284	17.4
Native Hawaiian/other Pacific Islander	14	11	78.6	3	21.4
White	1,707	1,416	83.0	291	17.0
Multiple races	96	81	84.4	15	15.6
Transmission category^d					
Male-to-male sexual contact	4,556	3,694	81.1	862	18.9
Injection drug use					
Male	256	199	77.5	58	22.5
Female	181	147	80.9	35	19.1
Male-to-male sexual contact and injection drug use	216	179	82.7	37	17.3
Heterosexual contact ^e					
Male	446	365	81.8	81	18.2
Female	1,036	846	81.6	191	18.4
Total^f	6,707	5,442	81.1	1,265	18.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through March of 2020 and are based on cases reported to CDC through June 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

^a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥13 years, by area of residence—41 states and the District of Columbia (preliminary)

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
			2019		
Alabama	596	471	79.0	125	21.0
Alaska	27	23	85.2	4	14.8
California	4,198	3,474	82.8	724	17.2
Colorado	459	381	83.0	78	17.0
Delaware	92	71	77.2	21	22.8
District of Columbia	249	223	89.6	26	10.4
Florida	4,405	3,691	83.8	714	16.2
Georgia	2,291	1,903	83.1	388	16.9
Hawaii	63	54	85.7	9	14.3
Illinois	1,257	1,046	83.2	211	16.8
Indiana	490	305	62.2	185	37.8
Iowa	100	91	91.0	9	9.0
Louisiana	889	732	82.3	157	17.7
Maine	29	27	93.1	2	6.9
Maryland	917	805	87.8	112	12.2
Massachusetts	521	474	91.0	47	9.0
Michigan	675	570	84.4	105	15.6
Minnesota	273	251	91.9	22	8.1
Mississippi	460	327	71.1	133	28.9
Missouri	487	375	77.0	112	23.0
Montana	25	22	88.0	3	12.0
Nebraska	81	65	80.2	16	19.8
Nevada	509	424	83.3	85	16.7
New Hampshire	31	28	90.3	3	9.7
New Mexico	147	132	89.8	15	10.2
New York	2,340	2,036	87.0	304	13.0
North Carolina	1,376	1,086	78.9	290	21.1
North Dakota	36	33	91.7	3	8.3
Ohio	972	815	83.8	157	16.2
Oklahoma	243	174	71.6	69	28.4
Oregon	198	176	88.9	22	11.1
Rhode Island	74	65	87.8	9	12.2
South Carolina	702	613	87.3	89	12.7
South Dakota	34	27	79.4	7	20.6
Tennessee	776	534	68.8	242	31.2
Texas	4,002	2,971	74.2	1,031	25.8
Utah	135	105	77.8	30	22.2
Virginia	822	648	78.8	174	21.2
Washington	489	436	89.2	53	10.8
West Virginia	144	106	73.6	38	26.4
Wisconsin	208	188	90.4	20	9.6
Wyoming	13	13	100	0	0.0
Total	31,835	25,991	81.6	5,844	18.4

Table 2b. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥13 years, by area of residence—41 states and the District of Columbia (preliminary) (cont)

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
2020 (January–March)					
Alabama	170	140	82.4	30	17.6
Alaska	9	9	100	0	0.0
California	844	737	87.3	107	12.7
Colorado	78	68	87.2	10	12.8
Delaware	36	27	75.0	9	25.0
District of Columbia	48	42	87.5	6	12.5
Florida	1,034	869	84.0	165	16.0
Georgia	388	335	86.3	53	13.7
Hawaii	9	8	88.9	1	11.1
Illinois	236	211	89.4	25	10.6
Indiana	116	79	68.1	37	31.9
Iowa	24	22	91.7	2	8.3
Louisiana	217	157	72.4	60	27.6
Maine	4	4	100	0	0.0
Maryland	191	177	92.7	14	7.3
Massachusetts	84	72	85.7	12	14.3
Michigan	146	115	78.8	31	21.2
Minnesota	67	59	88.1	8	11.9
Mississippi	117	85	72.6	32	27.4
Missouri	103	82	79.6	21	20.4
Montana	3	2	66.7	1	33.3
Nebraska	22	19	86.4	3	13.6
Nevada	74	60	81.1	14	18.9
New Hampshire	10	10	100	0	0.0
New Mexico	23	20	87.0	3	13.0
New York	528	470	89.0	58	11.0
North Carolina	299	246	82.3	53	17.7
North Dakota	9	8	88.9	1	11.1
Ohio	235	203	86.4	32	13.6
Oklahoma	43	33	76.7	10	23.3
Oregon	48	44	91.7	4	8.3
Rhode Island	11	8	72.7	3	27.3
South Carolina	196	180	91.8	16	8.2
South Dakota	7	6	85.7	1	14.3
Tennessee	190	132	69.5	58	30.5
Texas	649	345	53.2	304	46.8
Utah	36	18	50.0	18	50.0
Virginia	193	156	80.8	37	19.2
Washington	123	109	88.6	14	11.4
West Virginia	33	25	75.8	8	24.2
Wisconsin	50	47	94.0	3	6.0
Wyoming	4	3	75.0	1	25.0
Total	6,707	5,442	81.1	1,265	18.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through March of 2020 and are based on cases reported to CDC through June 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
2019					
California					
Alameda County	223	199	89.2	24	10.8
Los Angeles County	1,409	1,134	80.5	275	19.5
Orange County	246	199	80.9	47	19.1
Riverside County	262	212	80.9	50	19.1
Sacramento County	84	75	89.3	9	10.7
San Bernardino County	273	201	73.6	72	26.4
San Diego County	361	309	85.6	52	14.4
San Francisco County	207	199	96.1	8	3.9
District of Columbia	249	223	89.6	26	10.4
Florida					
Broward County	598	525	87.8	73	12.2
Duval County	272	209	76.8	63	23.2
Hillsborough County	267	229	85.8	38	14.2
Miami-Dade County	1,158	975	84.2	183	15.8
Orange County	471	372	79.0	99	21.0
Palm Beach County	237	188	79.3	49	20.7
Pinellas County	187	160	85.6	27	14.4
Georgia					
Cobb County	170	151	88.8	19	11.2
DeKalb County	327	272	83.2	55	16.8
Fulton County	565	479	84.8	86	15.2
Gwinnett County	194	166	85.6	28	14.4
Illinois					
Cook County	893	743	83.2	150	16.8
Indiana					
Marion County	209	110	52.6	99	47.4
Louisiana					
East Baton Rouge Parish	152	134	88.2	18	11.8
Orleans Parish	159	131	82.4	28	17.6
Maryland					
Baltimore City	192	166	86.5	26	13.5
Montgomery County	141	129	91.5	12	8.5
Prince George's County	271	238	87.8	33	12.2
Massachusetts					
Suffolk County	134	123	91.8	11	8.2
Michigan					
Wayne County	285	244	85.6	41	14.4
Nevada					
Clark County	448	369	82.4	79	17.6

Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Total No.	≥ 1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
2019 (cont)					
New York					
Bronx County	500	435	87.0	65	13.0
Kings County	474	402	84.8	72	15.2
New York County	343	303	88.3	40	11.7
Queens County	356	304	85.4	52	14.6
North Carolina					
Mecklenburg County	268	208	77.6	60	22.4
Ohio					
Cuyahoga County	158	141	89.2	17	10.8
Franklin County	217	197	90.8	20	9.2
Hamilton County	171	145	84.8	26	15.2
Pennsylvania					
Philadelphia County	431	367	85.2	64	14.8
Tennessee					
Shelby County	262	164	62.6	98	37.4
Texas					
Bexar County	356	255	71.6	101	28.4
Dallas County	738	558	75.6	180	24.4
Harris County	1,100	803	73.0	297	27.0
Tarrant County	292	218	74.7	74	25.3
Travis County	180	154	85.6	26	14.4
Washington					
King County	252	227	90.1	25	9.9

Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Total No.	≥ 1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
2020 (January–March)					
California					
Alameda County	49	43	87.8	6	12.2
Los Angeles County	287	246	85.7	41	14.3
Orange County	73	65	89.0	8	11.0
Riverside County	48	43	89.6	5	10.4
Sacramento County	2	2	100	0	0.0
San Bernardino County	29	23	79.3	6	20.7
San Diego County	64	59	92.2	5	7.8
San Francisco County	49	47	95.9	2	4.1
District of Columbia	48	42	87.5	6	12.5
Florida					
Broward County	139	124	89.2	15	10.8
Duval County	65	53	81.5	12	18.5
Hillsborough County	75	64	85.3	11	14.7
Miami-Dade County	244	202	82.8	42	17.2
Orange County	108	93	86.1	15	13.9
Palm Beach County	76	62	81.6	14	18.4
Pinellas County	43	38	88.4	5	11.6
Georgia					
Cobb County	16	14	87.5	2	12.5
DeKalb County	47	44	93.6	3	6.4
Fulton County	115	97	84.3	18	15.7
Gwinnett County	26	20	76.9	6	23.1
Illinois					
Cook County	166	151	91.0	15	9.0
Indiana					
Marion County	48	32	66.7	16	33.3
Louisiana					
East Baton Rouge Parish	40	33	82.5	7	17.5
Orleans Parish	25	19	76.0	6	24.0
Maryland					
Baltimore City	43	39	90.7	4	9.3
Montgomery County	24	24	100	0	0.0
Prince George's County	55	51	92.7	4	7.3
Massachusetts					
Suffolk County	27	26	96.3	1	3.7
Michigan					
Wayne County	73	57	78.1	16	21.9
Nevada					
Clark County	62	49	79.0	13	21.0

Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through March 2020 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
2020 (January–March) (<i>cont</i>)					
New York					
Bronx County	88	75	85.2	13	14.8
Kings County	135	117	86.7	18	13.3
New York County	76	66	86.8	10	13.2
Queens County	92	88	95.7	4	4.3
North Carolina					
Mecklenburg County	44	36	81.8	8	18.2
Ohio					
Cuyahoga County	47	42	89.4	5	10.6
Franklin County	58	50	86.2	8	13.8
Hamilton County	31	29	93.5	2	6.5
Pennsylvania					
Philadelphia County	94	80	85.1	14	14.9
Tennessee					
Shelby County	76	50	65.8	26	34.2
Texas					
Bexar County	77	42	54.5	35	45.5
Dallas County	173	103	59.5	70	40.5
Harris County	91	48	52.7	43	47.3
Tarrant County	63	33	52.4	30	47.6
Travis County	41	21	51.2	20	48.8
Washington					
King County	60	52	86.7	8	13.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through March of 2020 and are based on cases reported to CDC through June 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.